Biocon · NSE: BIOCON · BSE: 532523
Q3 FY25 results · Oct–Dec 2024
Biocon reported revenue from operations of ₹3,821.40 crore (down 3.3% from Q3 FY24) and net profit of ₹81.10 crore (down 89.2% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,821.40 | 3,953.70 | −3.3% | 3,590.40 | +6.4% |
| Other income | 34.80 | 565.50 | −93.8% | 32.50 | +7.1% |
| Total income | 3,856.20 | 4,519.20 | −14.7% | 3,622.90 | +6.4% |
| Profit before tax | 155.90 | 832.30 | −81.3% | 98.40 | +58.4% |
| Net profit for the period | 81.10 | 753.30 | −89.2% | 27.10 | +199.3% |
| Attributable to shareholders of the company | 25.10 | 660.00 | −96.2% | (16.00) | Turned profit |
| EPS, basic (₹) | 0.21 | 5.52 | −96.2% | (0.13) | Turned profit |
| Net margin (%) | 2.1 | 19.1 | 0.8 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 562.80 | 562.80 | +0.0% | 525.40 | +7.1% |
| Other income | 64.20 | 48.50 | +32.4% | 73.50 | −12.7% |
| Total income | 627.00 | 611.30 | +2.6% | 598.90 | +4.7% |
| Profit before tax | 603.90 | 32.90 | 18x | 20.90 | 29x |
| Net profit for the period | 584.00 | 24.00 | 24x | 3.20 | 182x |
| EPS, basic (₹) | 4.88 | 0.20 | 24x | 0.03 | 163x |
| Net margin (%) | 103.8 | 4.3 | 0.6 |
Consolidated
- Filed with BSE
- 31 Jan 2025, 13:05 IST
- Board meeting
- 30 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jan 2025, 13:05 IST
- Board meeting
- 30 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE